Best Drug Delivery Companies in Massachusetts, United States

Developer of a microarray patch platform for therapeutic delivery. The platform uses dissolvable tips made from advanced biomaterials for dose delivery and control. It aims to transform the delivery of therapies, offering a more convenient and comfortable patient experience. The platform seeks to eliminate the need for needles and refrigeration.

Funding rounds

• Mar 2026Series C$57.3M

Founders & team

Kathryn KosudaCo-Founder & CSO

Investors

RA Capital Management, Engine Ventures, Global Health Investment, SiteGround

Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.

Funding rounds

• May 2025Series B$153M
• Nov 2022Series A$45M
• Jun 2021Series A$52.1M
• May 2021Grant (prize money)$399.5K

Founders & team

Tasuku KitadaCo-founder

Investors

Playground Global, Alexandria, ANRI, Redmile Group, BeiGene, Camford Capital

Developer of a hydrogel drug delivery technology for ophthalmic treatment. It offers a lead product GMX-101 a retinal pigment epithelial (RPE) cell therapy that targets Geographic Atrophy.

Funding rounds

• Feb 2026Seed$13M
• Oct 2025Seed$542K
• Jan 2025Seed$1M
• Mar 2024Conventional Debt$1.9M

Founders & team

Nasim AnnabiCo-FounderReza DanaCo-FounderMax CotlerCEO

Investors

Safar Partners, HTL Biotechnology, Beacon Angels, TiE Boston, Boston Harbor Angels

Provider of a synthetic lipid-based drug delivery solution. The company is developing a new class of mRNA therapy using organ and cell-specific biodegradable LNP for immuno-oncology and regenerative medicine.

Funding rounds

• Sep 2025Seed$2.5M
• May 2023Seed$25M
• Feb 2022Seed$7.1M

Founders & team

Lou BrennerCEO

Investors

Massachusetts Avenue Capital, 5Y Capital, Hike Capital, Bopu Assets, IMO Ventures, WS Investment Company

Developer of gene-based therapeutics for multiple diseases. It offers genome engineering and chromatin regulation technology for developing delivery methods for enzymes and drugs to provide targeted gene editing in-vivo.

Pharmaceutical company developing a novel rescue drug for ulcerative colitis flares. Focused on gastroenterology, the company addresses unmet needs in disease management with a low competitive landscape. Their lead product, completing Phase 3 trials, aims for clinical remission with mucosal healing in just four weeks, offering a unique rescue option for ulcerative colitis patients, alone or with maintenance therapies. The company's patented suppository, utilizing a novel hydrocortisone acetate formulation and applicator, ensures consistent drug delivery and eliminates leakage. With a strong IP portfolio extending market exclusivity, they are poised to provide relief from debilitating rectal symptoms and improve the quality of life for those living with ulcerative colitis. This innovative approach solves an unmet need in ulcerative colitis treatment.

Digital platform transforming the delivery of biologic medicines. The company uses proprietary Hypercon microparticle platform that enables the formulation concentrated biologic drugs to administer treatments via simple subcutaneous injections..

Funding rounds

• Aug 2024Series C$112.3M
• Jun 2022Series B$40M
• Sep 2018Grant (prize money)$1.6M
• Jul 2017Grant (prize money)$224.9K

Founders & team

Chase CoffmanCo-Founder & CEOJason NorrisCo-Founder & COO

Investors

America’s Seed Fund, Novo Holdings, RA Capital Management, Royalty Pharma, SR One, TPG

Tech stack

Cart FunctionalitySquarespace CommerceSquarespaceStimulusPriority HintsHsts

Provider of fully synthetic RNA vaccine drug delivery technology. It has developed proprietary molecular systems for nucleic acid delivery and offers fully synthetic thermostable RNA vaccine technology, that delivers the nucleic acid into the patient’s cells upon vaccination. It encodes one or more proteins, to assemble antigens and drive immunity against various diseases.

Funding rounds

• Aug 2025Grant (prize money)$2.9M
• Apr 2025Grant (prize money)$300K
• Jun 2022Grant (prize money)$300K
• Feb 2022Grant (prize money)$2.2M

Founders & team

Christian W MandlCo-FounderJasdave ChahalCo-FounderKarl RupingCo-Founder & CEO

Investors

HHS, Inctank Ventures, Skyviews Life Science, XLIX Ventures, CEPI

Tech stack

WordpressMysqlPhpBold Page BuilderJetpackContact Form 7

Provider of drug delivery system for cancer treatment. It provides technologies for revolutionizing the treatment of inoperable, locally advanced solid tumours. By changing the route of administration, using novel localized drug-eluting systems able to provide mechanical support, and enhances the chemotherapeutic efficacy.

Funding rounds

• Mar 2025Series B$3M
• Nov 2023Series A$2.7M
• Dec 2022Series A$1.3M
• Aug 2022Grant (prize money)$14.2M

Founders & team

Laura IndolfiFounder and CEODavid TingFounder

Investors

CHV, Angel Physicians Fund, state.tx.us, BNSG Capital, JLABS, Springboard Enterprises

Tech stack

WordpressMysqlPhpGenesis ThemeElementorNginx

Developer of oral drug delivery formulations. The company has developed a swallowable pill that expands in the stomach to a ring shape, allowing it to dispense medication for longer than a week. Lyndra's internal development formulations are compounds for neuropsychology indications.

Funding rounds

• Dec 2023Series C$122.7M
• May 2023Series C$20.4M
• Jun 2021Series C$60.5M
• Mar 2020Grant (prize money)$1M

Founders & team

Andrew BellingerCo-FounderC TraversoCo-FounderRobert LangerCo-Founder

Investors

NIH, Polaris Partners, Quark Venture, GF Securities, Yonghua Capital, Partners HealthCare

Developer of therapeutic products and enabling technology platforms for healthcare. The company focuses on advancing health through sustainable science, integrating green enabling technology platforms with biotechnology. These platforms improve drug discovery and manufacturing, nanotechnology drug delivery, and pathogen safety. The company develops therapeutics for cancer, infectious diseases, and central nervous system disorders.

Developer of protein engineering technology creating targeted therapeutics for tissue repair. The company focuses on improving therapeutic delivery to enhance efficacy and reduce off-target side effects. It has developed material binding variants of recombinant proteins for clinical indications. These modified proteins enable safer and long-term delivery for vascular, soft tissue, and orthopedic repair.